Literature DB >> 8692821

IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus.

M S Lan1, C Wasserfall, N K Maclaren, A L Notkins.   

Abstract

IA-2 is a 105,847 Da transmembrane protein that belongs to the protein tyrosine phosphatase family. Immunoperoxidase staining with antibody raised against IA-2 showed that this protein is expressed in human pancreatic islet cells. In this study, we expressed the full-length cDNA clone of IA-2 in a rabbit reticulocyte transcription/translation system and used the recombinant radiolabeled IA-2 protein to detect autoantibodies by immunoprecipitation. Coded sera (100) were tested: 50 from patients with newly diagnosed insulin-dependent diabetes mellitus (IDDM) and 50 from age-matched normal controls. Sixty-six percent of the sera from patients, but none of the sera from controls, reacted with IA-2. The same diabetic sera tested for autoantibodies to islet cells (ICA) by indirect immunofluorescence and glutamic acid decarboxylase (GAD65Ab) by depletion ELISA showed 68% and 52% positivity, respectively. Up to 86% of the IDDM patients had autoantibodies to IA-2 and/or GAD65. Moreover, greater than 90% (14 of 15) of the ICA-positive but GAD65Ab-negative sera had autoantibodies to IA-2. Absorption experiments showed that the immunofluorescence reactivity of ICA-positive sera was greatly reduced by prior incubation with recombinant IA-2 or GAD65 when the respective antibody was present. A little over one-half (9 of 16) of the IDDM sera that were negative for ICA were found to be positive for autoantibodies to IA-2 and/or GAD65, arguing that the immunofluorescence test for ICA is less sensitive than the recombinant tests for autoantibodies to IA-2 and GAD65. It is concluded that IA-2 is a major islet cell autoantigen in IDDM, and, together with GAD65, is responsible for much of the reactivity of ICA with pancreatic islets. Tests for the detection of autoantibodies to recombinant IA-2 and GAD65 may eventually replace ICA immunofluorescence for IDDM population screening.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8692821      PMCID: PMC39028          DOI: 10.1073/pnas.93.13.6367

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies.

Authors:  G F Bottazzo; A Florin-Christensen; D Doniach
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

Review 2.  An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs.

Authors:  M Kozak
Journal:  Nucleic Acids Res       Date:  1987-10-26       Impact factor: 16.971

3.  Antibodies to a Mr-64,000 islet cell protein in Swedish children with newly diagnosed type 1 (insulin-dependent) diabetes.

Authors:  M Christie; M Landin-Olsson; G Sundkvist; G Dahlquist; A Lernmark; S Baekkeskov
Journal:  Diabetologia       Date:  1988-08       Impact factor: 10.122

4.  A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes.

Authors:  W J Riley; N K Maclaren; J Krischer; R P Spillar; J H Silverstein; D A Schatz; S Schwartz; J Malone; S Shah; C Vadheim
Journal:  N Engl J Med       Date:  1990-10-25       Impact factor: 91.245

5.  Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase.

Authors:  S Baekkeskov; H J Aanstoot; S Christgau; A Reetz; M Solimena; M Cascalho; F Folli; H Richter-Olesen; P De Camilli; P D Camilli
Journal:  Nature       Date:  1990-09-13       Impact factor: 49.962

6.  Antibodies to GAD and tryptic fragments of islet 64K antigen as distinct markers for development of IDDM. Studies with identical twins.

Authors:  M R Christie; R Y Tun; S S Lo; D Cassidy; T J Brown; J Hollands; M Shattock; G F Bottazzo; R D Leslie
Journal:  Diabetes       Date:  1992-07       Impact factor: 9.461

7.  Identification and cloning of a granule autoantigen (carboxypeptidase-H) associated with type I diabetes.

Authors:  L Castaño; E Russo; L Zhou; M A Lipes; G S Eisenbarth
Journal:  J Clin Endocrinol Metab       Date:  1991-12       Impact factor: 5.958

8.  Antibodies to a 64,000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes.

Authors:  S Baekkeskov; M Landin; J K Kristensen; S Srikanta; G J Bruining; T Mandrup-Poulsen; C de Beaufort; J S Soeldner; G Eisenbarth; F Lindgren
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

9.  Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment.

Authors:  J Lu; Q Li; H Xie; Z J Chen; A E Borovitskaya; N K Maclaren; A L Notkins; M S Lan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

10.  64,000 Mr autoantibodies as predictors of insulin-dependent diabetes.

Authors:  M A Atkinson; N K Maclaren; D W Scharp; P E Lacy; W J Riley
Journal:  Lancet       Date:  1990-06-09       Impact factor: 79.321

View more
  60 in total

Review 1.  Treatment of an autoimmune disease with "classical" T cell veto: a proposal.

Authors:  U D Staerz; Y Qi
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

2.  Autoimmune type 1 diabetes: resolved and unresolved issues.

Authors:  A L Notkins; A Lernmark
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

3.  IA-2 is not required for the development of diabetes in NOD mice.

Authors:  A Kubosaki; J Miura; Abner L Notkins
Journal:  Diabetologia       Date:  2003-11-12       Impact factor: 10.122

Review 4.  Structural genomics of protein phosphatases.

Authors:  Steven C Almo; Jeffrey B Bonanno; J Michael Sauder; Spencer Emtage; Teresa P Dilorenzo; Vladimir Malashkevich; Steven R Wasserman; S Swaminathan; Subramaniam Eswaramoorthy; Rakhi Agarwal; Desigan Kumaran; Mahendra Madegowda; Sugadev Ragumani; Yury Patskovsky; Johnjeff Alvarado; Udupi A Ramagopal; Joana Faber-Barata; Mark R Chance; Andrej Sali; Andras Fiser; Zhong-yin Zhang; David S Lawrence; Stephen K Burley
Journal:  J Struct Funct Genomics       Date:  2007-12-05

5.  Selective screening of secretory vesicle-associated proteins for autoantigens in type 1 diabetes: VAMP2 and NPY are new minor autoantigens.

Authors:  Hiroki Hirai; Junnosuke Miura; Yafang Hu; Helena Larsson; Karin Larsson; Ake Lernmark; Sten-A Ivarsson; Tianxia Wu; Albert Kingman; Athanasios G Tzioufas; Abner L Notkins
Journal:  Clin Immunol       Date:  2008-03-24       Impact factor: 3.969

6.  Deletion of the secretory vesicle proteins IA-2 and IA-2beta disrupts circadian rhythms of cardiovascular and physical activity.

Authors:  Soo Mi Kim; Andrea Power; Timothy M Brown; Cara M Constance; Steven L Coon; Takuya Nishimura; Hiroki Hirai; Tao Cai; Christoph Eisner; David R Weaver; Hugh D Piggins; David C Klein; Jürgen Schnermann; Abner L Notkins
Journal:  FASEB J       Date:  2009-05-11       Impact factor: 5.191

7.  IA-2beta, but not IA-2, is induced by ghrelin and inhibits glucose-stimulated insulin secretion.

Authors:  Asako Doi; Takeshi Shono; Masahiro Nishi; Hiroto Furuta; Hideyuki Sasaki; Kishio Nanjo
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-17       Impact factor: 11.205

8.  Assignment of the IA-2 gene encoding an autoantigen in IDDM to chromosome 2q35.

Authors:  M S Lan; W S Modi; H Xie; A L Notkins
Journal:  Diabetologia       Date:  1996-08       Impact factor: 10.122

Review 9.  Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?

Authors:  Lucienne Chatenoud
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

10.  Clustering of immunological, metabolic and genetic features in latent autoimmune diabetes in adults: evidence from principal component analysis.

Authors:  Giovanni Mario Pes; Alessandro Palmerio Delitala; Alessandra Errigo; Giuseppe Delitala; Maria Pina Dore
Journal:  Intern Emerg Med       Date:  2015-11-26       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.